Central Nervous System Drugs Market Global Briefing 2017Including: Anaesthetics, Analgesics, Anti-Parkinson drugs, Anti-Epileptics, Other CNS drugs.Covering: Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer Inc., Novartis AG, Shire Plc., UCB S.A., Eli Lilly And Company, Sanofi S.A., Daiichi Sankyo Company, Limited
The global central nervous system drugs market is expected to reach around $82 billion in 2020. Going forward, the growth of this market can be attributed to steps taken by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) to offer allotment of special regulatory designations for Central Nervous System disorders which will help in the faster entry of drugs into the market for treatment of serious nervous system related conditions.
Central Nervous System Drugs Market Global Briefing provides strategists, marketers and senior management with the critical information they need to assess the global central nervous system drugs sector.
Reasons to Purchase
- Get up to date information available on the central nervous system drugs market globally.
- Identify growth segments and opportunities.
- Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
- Develop strategies based on likely future developments.
- Gain a global perspective on the development of the market.
Central Nervous System Drugs Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.
The market characteristics section of the report defines and explains the market.
The market size section gives the central nervous system drugs market revenues, covering both the historic growth of the market and forecasting the future.
Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.
The trends and strategies section highlights the likely future developments in the central nervous system drugs market and suggests approaches. Scope
Markets Covered: Anaesthetics, Analgesics, Anti-Parkinson drugs, Anti-Epileptics, Other CNS drugs.
Companies Mentioned: Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer Inc., Novartis AG, Shire Plc., UCB S.A., Eli Lilly And Company, Sanofi S.A., Daiichi Sankyo Company Limited
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.